Conno Christou operates with deliberate precision, leaving no aspect of his health to chance. He meticulously tracks his sleep using a Whoop band, cross-referencing data with an Oura ring, and undergoes comprehensive checks of nearly 100 biomarkers annually. For four consecutive years, he adhered to the rigorous bloodwork protocols advocated by leading longevity researchers such as Peter Attia and Rhonda Patrick, diligently optimizing his supplements, circadian rhythm, and protein intake.
At 35, while actively building his second company, Christou was as deeply immersed in the latest health research as anyone he knew. His most recent checkup in 2025 yielded impeccable results. "It was the best I’d had in years," he states.
Then, following a workout, his arm unexpectedly swelled.
Initially, he dismissed it as minor. A week elapsed before he consulted a doctor, who identified two blood clots in his veins and scheduled surgery. However, the pre-operative examinations radically altered the course of events. A doctor re-entered the room to inform him that the procedure was cancelled.
"We see an 11-by-11-by-8 centimeter mass behind your sternum," the doctor announced.
A subsequent biopsy confirmed a diagnosis Christou had never even considered: an aggressive, rapidly progressing form of non-Hodgkin’s lymphoma. This rare condition, affecting approximately one in 420,000 individuals, is attributed to a random genetic mutation with no discernible link to lifestyle, diet, or stress factors.
The tumor had developed in only about three months, and in just three more weeks, it would have advanced to stage four.
"Lucky in my unluckiness," Christou recently shared with this editor from his part-time residence in Athens. "It was only found because I went in for something else entirely."
This experience initiated a profound education into the limitations of the conventional medical system and the empowering potential of modern tools for a determined patient.
His initial oncologist, a highly respected specialist, recommended the less intensive of two available chemotherapy regimens. Christou scheduled his first infusion within three days. Yet, the night before treatment was to begin, he sought a second opinion.
The second physician offered an immediate and unequivocal recommendation: the more aggressive regimen, involving continuous in-hospital infusions over six months, cycling every three weeks. This recommendation was based on Christou’s specific pathology. The lighter treatment had an approximate 60% success rate for his condition, while the aggressive approach elevated that figure to around 85%. Two world-class doctors presented recommendations that were diametrically opposed.
"As founders, we hold the wheel," Christou reflects, referring to the common tendency to accept initial medical advice without question, and why a more proactive stance is often necessary. "You hear many things. You don’t have to follow the first advice."
He did not, however, simply adopt the second physician’s advice either. Over the ensuing two days, he meticulously gathered a total of 12 opinions, leveraging his professional network to reach out to hematologists and oncologists across the U.S. and internationally, calling in every favor he could. Eleven of the twelve specialists advocated for the harder treatment path. He chose it, describing the decision not as courageous, but as logical. When the stakes are existential, he asserts, one must collect data.
Throughout six months of treatment, Christou approached chemotherapy with the same strategic mindset he applied to building a company: as a series of sprints within a marathon, each cycle finite, each week rich with data points. He also drew upon his mandatory 25-month military service in Cyprus at age 18, telling himself he would be a "good soldier." "Trust the process. Six cycles. Get through it," he resolved.
He continued wearing his Whoop device, finding it remarkably accurate in predicting days when his immune system would be severely compromised, sometimes flagging these downturns before symptoms even manifested. He maintained a detailed symptom journal using voice transcription, meticulously logging every bodily change, side effect, medication, and counter-medication. His focus narrowed to three critical variables: sleep, nutrition, and, most importantly, psychology. ("It moves the needle more than anything," Christou emphasized. "I never asked ‘why me’ — not once. That question has no useful answer.")
He systematically fed all this information — blood results, scan data, wearable output, and journal entries — into Claude, an AI chatbot. His reliance on chatbots for medical insights is not isolated; a public opinion poll released in March indicated that one-third of American adults now utilize such tools for health information and advice. Online accounts increasingly suggest that for some patients, AI is providing solutions that traditional systems have not.
Experts, however, urge caution. Danielle Bitterman, clinical lead for data science and AI at Mass General Brigham, recently informed the New York Times that general-purpose chatbots are "frequently wrong" and "have not been thoroughly evaluated" for personalized diagnoses.
Christou concurs with this cautionary perspective. "It didn’t replace the doctors," he states, but it "helped me ask the right questions."
For a condition as rare as his—one an oncologist might encounter only once a year—accessing an AI model that had assimilated the entire body of medical literature was, he insists, fundamentally different from a simple Google search.
This distinction proved pivotal at the culmination of his treatment. His final PET scan, crucial for detecting active disease, yielded ambiguous results. His oncologist began discussing a potential second line of therapy, possibly radiotherapy near his heart and lungs—an alarming prospect.
Christou, once again, undertook extensive research. He discovered that for this specific type of lymphoma, the false-positive rate on end-of-treatment PET scans is approximately 60%—a statistic that continues to astound him. "It’s 2026," he exclaims. "Sixty percent."
He uploaded all three of his PET scans and his MRI into Claude. The AI flagged a known yet often overlooked phenomenon: in patients under 40 recovering from this type of lymphoma, the thymus gland can reactivate post-chemotherapy, appearing on imaging as what seems to be active disease. Given his age and specific scan characteristics, the model assigned a roughly 90% probability to this explanation.
He then sought three additional opinions. The fourth doctor confirmed the AI's insight: thymus rebound. There was no active disease, no radiotherapy was required. He was clear.
Christou is still processing the profound implications of the past year on his health, his professional life, and his perception of time. He founded Keragon, his current company—an AI-powered platform designed to automate administrative operations for medical practices—prior to his diagnosis.
Yet, navigating the healthcare system as a patient has afforded him a fresh perspective. He witnessed nurses and doctors overwhelmed by administrative duties unrelated to patient care. He received the identical chemotherapy protocol as an 80-year-old woman, with side effects managed by a cascading sequence of additional drugs, each introducing its own complications. He is convinced that future generations will look back at this era of treatment with profound discomfort.
He now largely dedicates Sundays to rest and personal time. He strives to be present—at lunch with friends, at home with his dog, and in conversations that he might once have viewed as distractions from work. A venture capitalist friend once offered him advice years ago that he frequently recalled during treatment: "Be happy now." He admits it is one of the most challenging directives, yet he finally grasps its profound significance.
Christou expresses a genuine willingness to connect with anyone undergoing a similar experience, to share insights and compare notes.
"It’s not happening in 10 years," he asserts, referring to the current capabilities of AI for proactive patients. "It’s happening today."
The Editorial Staff at AIChief is a team of professional content writers with extensive experience in AI and marketing. Founded in 2025, AIChief has quickly grown into the largest free AI resource hub in the industry.